Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Personalis, Inc.

Market Cap 1.03B 884M 813M 763M 1.43B 96.89B 1.45B 9.61B 3.76B 47.45B 3.85B 3.77B 164B P/E Ratio 2026 *
-9.57x
P/E Ratio 2027 * -10.9x
Enterprise Value 864M 745M 686M 643M 1.21B 81.7B 1.22B 8.11B 3.17B 40.01B 3.24B 3.18B 138B EV / Sales 2026 *
11x
EV / Sales 2027 * 8.52x
Free-Float
72.96%
Yield 2026 *
-
Yield 2027 * -
1 day+2.09%
1 week-2.49%
Current month-14.12%
1 month+53.93%
3 months+45.68%
6 months+15.45%
Current year+22.99%
1 week 9.14
Extreme 9.14
10.31
1 month 6.39
Extreme 6.39
12.53
Current year 4.96
Extreme 4.955
12.53
1 year 3.84
Extreme 3.84
12.53
3 years 0.89
Extreme 0.8906
12.53
5 years 0.89
Extreme 0.8906
28.47
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 2023-03-01
Chief Executive Officer 65 2022-12-30
President 55 2026-03-12
Director TitleAgeSince
Director/Board Member 79 2019-04-30
Chairman 76 2022-05-16
Director/Board Member 72 2021-03-05
Date Insider Type Main position Quantity % Market Cap.
06-03Fiscal year

Chief Financial Officer

120,000 0.1353%
05-28Fiscal year

Chief Financial Officer

116,397 0.1313%
05-28Fiscal year

Chief Executive Officer

240,273 0.2710%
Change 5-day change 1-year change 3-year change Capi.($)
+2.09%-2.49%+62.90%+355.35% 1.03B
+0.88%+0.91%-11.85%-11.95% 43.58B
+4.02%+7.79%+294.33%+536.67% 34.03B
-1.69%-2.89%+13.70%-17.71% 29.77B
+1.41%-0.96%-0.53%+33.41% 29.82B
+1.16%+9.79%+14.27%+22.28% 25.42B
+2.40%+8.49% - - 13.87B
+0.03%+2.10%+56.75%+111.91% 13.35B
-0.95%-3.39%+2.51%+2.08% 12.85B
+0.93%+0.57%+107.81%+77.40% 12.22B
Average +0.58%+1.44%+59.99%+123.27% 21.59B
Weighted average by Cap. +0.37%+1.83%+61.49%+106.93%

Financials

2026 *2027 *
Net sales 78.74M 67.87M 62.46M 58.6M 110M 7.44B 111M 738M 288M 3.64B 296M 289M 12.61B 111M 95.68M 88.06M 82.61M 155M 10.49B 157M 1.04B 407M 5.14B 417M 408M 17.78B
Net income -107M -92.23M -84.88M -79.63M -150M -10.11B -151M -1B -392M -4.95B -402M -393M -17.14B -96.4M -83.09M -76.47M -71.74M -135M -9.11B -136M -904M -353M -4.46B -362M -354M -15.44B
Net Debt -161M -139M -128M -120M -225M -15.19B -227M -1.51B -589M -7.44B -603M -590M -25.74B -79.83M -68.81M -63.33M -59.41M -112M -7.54B -113M -749M -292M -3.69B -300M -293M -12.78B
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
26-06-15 9.790 $ +2.09% 2,519,540
26-06-12 9.590 $ +1.80% 1,965,220
26-06-11 9.420 $ -1.98% 3,685,184
26-06-10 9.610 $ -1.44% 2,020,968
26-06-09 9.750 $ -2.89% 4,011,394
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.790USD
Average target price
10.86USD
Spread / Average Target
+10.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!